Here are 1-3 brief analogies for Pulmonx:

• Like an Intuitive Surgical, but focused on providing a minimally invasive device solution for severe emphysema rather than robotic surgery.
• Similar to Shockwave Medical, but instead of treating cardiovascular calcification, it develops innovative, minimally invasive devices to treat severe emphysema.
• Imagine a very specialized Medtronic, dedicated solely to treating severe emphysema with its unique lung valves and assessment tools.

• Zephyr Endobronchial Valve: A solution for the treatment of bronchoscopic in adult patients with hyperinflation associated with severe emphysema.
• Chartis Pulmonary Assessment System: A balloon catheter and console system with flow and pressure sensors used to assess the presence of collateral ventilation.
• StratX Lung Analysis Platform: A cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume.

Pulmonx Corporation (LUNG) is a medical technology company that provides minimally invasive devices and analysis platforms for the treatment of chronic obstructive pulmonary diseases, specifically severe emphysema. Given the nature of its products (e.g., Zephyr Endobronchial Valve, Chartis Pulmonary Assessment System, StratX Lung Analysis Platform), the company primarily sells to healthcare providers rather than directly to individual patients.

Therefore, Pulmonx's major customers are not individual consumers but rather institutional purchasers within the healthcare industry. These can be broadly categorized as:

• Hospitals: Especially those with specialized pulmonology departments or interventional bronchoscopy capabilities, where complex procedures using devices like the Zephyr Valve are performed.
• Specialized Lung Clinics and Emphysema Treatment Centers: Facilities that focus on advanced care for respiratory diseases and offer comprehensive treatment options for conditions like severe emphysema.
• Healthcare Systems: Large integrated networks of hospitals, clinics, and other healthcare facilities that make centralized purchasing decisions for their various components.

Glen French, President & Chief Executive Officer

Glen French has over 30 years of experience in the medical device industry. He served as Pulmonx's President and Chief Executive Officer from December 2014 to March 2023, and resumed the position in October 2025, having maintained continuous service on the company's Board. French previously co-founded and served as Chief Executive Officer of Asthmatx, Inc., which was acquired by Boston Scientific Corporation. He also co-founded and led Broncus Technologies, Inc. and was a co-founder and board member of NDO Surgical, Inc. French has co-founded, built, and sold three medical device companies and took a fourth company (Pulmonx) public.

Derrick Sung, Ph.D., Chief Operating Officer & Chief Financial Officer

Derrick Sung brings over 20 years of finance, strategy, and commercial experience across various facets of the medical device industry. He has served as Chief Operating Officer and Chief Financial Officer for Pulmonx since November 2025, and previously served as Chief Financial Officer for Pulmonx from July 2018 to October 2023. Prior to rejoining Pulmonx, Sung served as Chief Financial Officer at Aerin Medical until November 2025. Before his initial tenure at Pulmonx, he was Executive Vice President, Strategy & Corporate Development at iRhythm Technologies, Inc. (NASDAQ: IRTC), where he helped guide the company through a successful IPO. He also spent seven years on Wall Street as a senior equity research analyst covering the medical device sector for Sanford C. Bernstein & Company.

Lisa Paul, Chief People Officer

Lisa Paul possesses over 30 years of Human Resources leadership experience within medical device, technology, services, and communications companies. Before joining Pulmonx, Paul was the Chief People Officer at Natus Medical Incorporated from 2019 to 2022 and Executive Vice President, Chief Human Resources Officer at Oclaro Technology Incorporated from 2014 to 2018.

Geoffrey Beran Rose, Chief Commercial Officer

Geoffrey Beran Rose serves as the Chief Commercial Officer for Pulmonx Corporation. Detailed background information regarding founding or selling companies, or a pattern of managing private equity-backed companies, was not available in the provided search results.

David Lehman, General Counsel & Secretary

David Lehman holds the position of General Counsel and Secretary at Pulmonx. Detailed background information regarding founding or selling companies, or a pattern of managing private equity-backed companies, was not available in the provided search results.

Here are the key risks to Pulmonx Corporation (LUNG):

1. Ongoing Net Losses and Cash Burn: Pulmonx Corporation has a history of significant net losses and anticipates these losses to continue for the foreseeable future. The company consistently reports negative operating and net income, indicating that the cost of scaling its specialized medical device business, particularly in the U.S. market, exceeds its gross profit. This persistent need for capital and negative free cash flow presents a runway constraint, as the company needs to outrun its cash burn rate before potentially requiring additional capital.
2. Reliance on Zephyr Valve and Challenges in Market Adoption/Commercial Execution: The financial health and future success of Pulmonx are highly dependent on the commercial success and broad market acceptance of its Zephyr Endobronchial Valve. The company has experienced top-line weakness, especially in the United States, attributed to soft procedural volumes and internal operational and sales disruptions, including high turnover within its sales organization. Resistance from hospitals, physicians, and patients to adopt new treatment methods could also limit growth prospects. International markets, such as China, have also presented volatility due to inventory and regulatory issues.
3. Product-Related Risks, Regulatory Hurdles, and Competition: The Zephyr Endobronchial Valve procedure, while minimally invasive, carries inherent product risks including potential complications like pneumothorax (collapsed lung) and, in rare cases, death. These risks represent ongoing regulatory and liability concerns. As a medical technology company, Pulmonx is subject to stringent regulatory processes; any delays or failures in obtaining or maintaining regulatory approvals for its current or future products could materially impact its business. Furthermore, the company operates in a competitive medical devices industry, facing pressures from other treatments and technologies.

Pulmonx Corporation (NASDAQ: LUNG) primarily addresses a significant global market for its innovative treatments for severe emphysema.

• The estimated global addressable market opportunity for Pulmonx's Zephyr Endobronchial Valves, which includes the use of the Chartis Pulmonary Assessment System and StratX Lung Analysis Platform for patient selection, is approximately $12 billion.
• This market size is based on an estimated 1.2 million severe emphysema patients globally who may be eligible for treatment with Zephyr Valves out of approximately 3.2 million severe emphysema patients.
• In the United States, there are an estimated 1.5 million patients with severe emphysema.
• An investigational AeriSeal System, which is in development, has the potential to expand Pulmonx's total addressable market by approximately 20% globally by addressing patients with collateral ventilation.

Pulmonx Corporation (LUNG) is expected to drive future revenue growth over the next 2-3 years through several key initiatives:

1. Increased Adoption and Commercial Momentum of the Zephyr Valve in the U.S. Market: The company anticipates re-accelerated U.S. sales in the latter half of 2026, following efforts to address past execution issues and implement a renewed U.S. sales focus. Pulmonx aims to regain commercial momentum and foster broader adoption of its Zephyr Valve therapy in the United States.
2. Expansion and Growth in International Markets: International revenue has demonstrated consistent growth, with significant increases in recent quarters. Pulmonx is actively expanding its presence in high-potential international markets, including Japan and China, which are expected to fuel future top-line growth for the Zephyr Valve, with anticipated resumption of China sales in the latter half of 2026 after certificate renewal.
3. Launch and Adoption of New Therapeutic Products: A significant driver of medium-term growth is the development and commercialization of new products, notably the AeriSeal program. The AeriSeal CONVERT II pivotal trial is a priority, with completion expected in 2027. Management believes this program could expand the company's global total addressable market by approximately 20%.
4. Leveraging Patient Identification and Assessment Platforms: Pulmonx's Chartis Pulmonary Assessment System and StratX Lung Analysis Platform are crucial for identifying suitable patients for Zephyr Valve treatment. By building an entire ecosystem around patient identification, assessment, and treatment, the company aims to streamline the patient selection process and further drive Zephyr Valve procedure volumes.

Here is a summary of Pulmonx's (LUNG) capital allocation decisions over the last 3-5 years:

Share Issuance

• Pulmonx completed its Initial Public Offering (IPO) in October 2020, issuing 11,500,000 shares of common stock at $19.00 per share, resulting in gross proceeds of approximately $218.5 million.
• The company regularly grants equity awards, such as Restricted Stock Units (RSUs) and Performance Stock Units (PSUs), to employees and executives. For instance, in December 2025, 1,625,000 shares were granted under its 2025 Inducement Plan to new hires, including 1,225,000 RSUs and up to 400,000 PSUs for the Chief Financial Officer.
• The number of outstanding shares has increased steadily, from 36.63 million in 2021 to 40.93 million in 2025, and approximately 42.24 million in March 2026, largely due to these equity grants.

Inbound Investments

• In March 2026, Pulmonx closed a five-year credit facility for up to $60 million with Perceptive Advisors, which included an initial $40 million term loan drawn to refinance existing debt.
• This credit facility also provides an option to draw an additional $20 million through the end of 2027, contingent upon achieving certain revenue milestones, and extends the company's debt maturity to 2031.

Capital Expenditures

• Pulmonx reported capital expenditures of approximately -$0.09 million USD in the most recent quarter and -$452,000 in the last 12 months.
• These negative figures indicate that the cash inflow from the sale of property, plant, and equipment exceeded the cash outflow for new capital asset purchases during these periods.